loader
Page is loading...
Print Logo Logo
Mike Zogby
OVERVIEW

Michael C. Zogby

He/Him

Partner

New Jersey

67 E. Park Place         
Suite 1000
Morristown, NJ 07960

Philadelphia

1717 Arch Street
Suite 4900
Philadelphia, PA 19103-2825

New York

390 Madison Avenue
12th Floor
New York, NY 10017-2509

P 973-775-6110

F 973-775-6102

Multinational clients turn to trial attorney Michael C. Zogby to litigate and manage risk related to aggregated proceedings, product liability risks, and mass tort claims. Mike is an advocate for clients in the life sciences industry, and he also counsels clients in commercial and consumer disputes, class actions, intellectual property and antitrust challenges, and trade secret violations.

OVERVIEW

Multinational clients turn to trial attorney Michael C. Zogby to litigate and manage risk related to aggregated proceedings, product liability risks, and mass tort claims. Mike is an advocate for clients in the life sciences industry, and he also counsels clients in commercial and consumer disputes, class actions, intellectual property and antitrust challenges, and trade secret violations.

Mike serves as partner-in-charge of Barnes & Thornburg’s New Jersey and Philadelphia offices and is Co-Chair of the firm’s Trials & Global Disputes practice group. Mike represents major pharmaceutical, medical device, life sciences, biotechnology, consumer products, manufacturing and chemical companies in product liability, mass tort, toxic tort, environmental litigation, and business disputes alleging negligence, failure to warn, strict liability, design and manufacturing defects, fraud, consumer protection, breach of warranty, wrongful death, antitrust, intellectual property, E-Discovery, punitive damages, and trade secrets challenges.

He has received national rankings in Chambers and Partners for Products Liability and Mass Tort USA Nationwide and included as a Leading Lawyer by The Legal 500, where clients recognized Mike’s “business savvy” approach and knowing “what clients want and how they want to see it.”

Chambers 2023 has indicated that Mike’s "approach to complex cases is strategic and well thought out. He is incredibly responsive and truly cares about the case and the client," and one client said "I have nothing but the utmost respect for Mike. He is incredibly diligent and thoughtful and someone whose judgment I trust."  Chambers USA 2022 states that Mike “knows the law and the field very well” and “is very thorough and good at anticipating issues. He is also particularly diligent and able.” In previous editions, Chambers USA noted, “His attention to detail is great, and he's well respected by peers and the court" and “He is outstanding, and has a great skill set.” In addition, his ranking stated: “He is perhaps one of the most diligent people I have ever met. He is responsive, very client-focused, very intelligent and practical – a really nice lawyer to partner with.” “He is extremely organized, extremely technical and just a great guy – someone who as a company you are proud to put before a judge.”

As trial counsel, Mike works diligently with scientists and other experts to develop persuasive defense arguments for complex litigation. In addition, Mike counsels clients in the U.S., Asia, and Europe on a variety of privacy, security, and e-discovery issues. He coordinates cross-border trial issues and discovery involving multidistrict litigation in highly regulated industries. 

Notably, Mike has a broad range of trial and appellate experience in intellectual property and antitrust litigation representing life sciences, pharmaceutical, and other manufacturers in patent infringement, false marking, trade secret, and Robinson-Patman act proceedings. 

Mike is a past chair of the product liability and mass tort and pharmaceutical and life sciences groups at an AmLaw 100 firm, and past deputy chair of the product liability and mass tort group and chair of the health and life sciences industry litigation team at an AmLaw 50 firm. He chaired the marketing, labeling, and advertising team, the New Jersey mentorship committee, served as a diversity committee sponsor, and worked as a steering committee member on the global Japanese engagement team.

Mike is Co-Chair of the BTMENA talent resource group, which provides mentoring, learning and development opportunities for the firm’s Middle Eastern and North African attorneys, staff and allies. He frequently contributes to journals and industry panel discussions on existing and emerging topics in life sciences, trial advocacy, cross-border litigation and product liability law. Mike serves on the faculty of the National Trial Advocacy College at the University of Virginia School of Law, and has lectured on trial ethics and cybersecurity for practitioners at Fordham University School of Law.

Product Liability, Mass Tort Multidistrict, and Aggregated Litigation

Mike has significant experience defending major pharmaceutical, medical device, life sciences, biotechnology and chemical companies in product liability actions filed by consumer and government parties alleging:

  • Negligence
  • Failure to warn
  • Strict liability
  • Design and manufacturing defects
  • Fraud
  • Consumer protection
  • False Claims Act
  • Breach of warranty
  • Wrongful death
  • Punitive damages

Mike’s product experience includes defending prescription medications, over-the-counter products, orthopaedic implants and other medical devices before state and federal courts and in mass tort, class action, attorney general and multidistrict proceedings. He has served as lead, liaison, U.S. discovery, and Japanese discovery counsel in litigations throughout the United States.

International Privacy, Security, and E-Discovery

Multinational clients value Mike’s deep experience handling cross-border e-discovery issues. He advises on the EU’s General Data Protection Regulations (GDPR), Japan’s Act on the Protection of Personal Information, and other foreign privacy laws. He counsels clients on discovery issues, document and data preservation requirements, proportionality considerations, and privilege protections. He also partners with business units to respond to trial and discovery issues expediently and efficiently.

Intellectual Property and Antitrust Litigation

Mike has a broad range of trial and appellate experience representing pharmaceutical and life sciences companies in patent infringement, Robinson-Patman Act, false marking, trade secret, intellectual property, and antitrust actions in federal courts and multidistrict proceedings.

Complex Commercial Litigation

Mike has defended large law and accounting firms in professional liability actions, and hospitals and health care organizations in tortious interference, unfair competition, civil conspiracy, and ERISA litigation before courts and administrative agencies. He has also represented corporate clients in business disputes, commercial, employment, insurance coverage, environmental, and real estate litigation matters.

Professional and Community Involvement

Board of directors member, Product Liability Advisory Council (PLAC)

Member, Products Liability Advisory Council (PLAC) Membership Committee

Member, Product Liability Advisory Council (PLAC) Case Selection Committee

Member, International Association of Defense Counsel (IADC)

Member, IADC Intellectual Property Committee 2022 Conference Planning Committee

Board member, Trial Attorneys of America

Board of trustees member, Trial Attorneys of New Jersey

Member, New Jersey Civil Justice Institute Advisory Board

Co-Chair, American Bar Association (ABA) Mass Torts Litigation Pharmaceutical, and Medical Device Committee 

Organizer, ABA Biotech, Pharma, and Medical Device Conference 

Board of directors member, National Arab American Bar Association

Member, American Task Force on Lebanon (ATFL)

Appointed member, New Jersey State Bar Association Class Actions Special Committee

Appointed member of Antitrust Special Committee, New Jersey State Bar Association Antitrust Special Committee

Appointed member, New Jersey State Bar Association Equity Jurisprudence Committee

Faculty member, National Trial Advocacy College at the University of Virginia School of Law 

Lecturer, Fordham University School of Law in trial ethics and cybersecurity

Board of trustees member, Tri-County Scholarship Fund

Organizer, Tri-County Scholarship Fund Lawyers for Tri-County Awards Event

Member, Sedona Conference Working Group 6 Drafting and Brainstorming Committee (Commentary on Proportionality in Cross-Border Discovery and Investigations)

Member, Sedona Conference E-Discovery Working Group 1 and Mass Torts and Punitive Damages Working Group 8 Commentary

Member, George Washington School of Law James F. Humphries Complex Litigation Center Discovery Proportionality Model Working Group

Member, Law360 Product Liability Advisory Board 

Former member, Law360 Life Sciences Editorial Advisory Board

Member, Rabiej Litigation Law Center Board

Member, Life Sciences PA

Member, Health Institute of New Jersey

Member, Morris County Chamber of Commerce  

Member, New Jersey Supreme Court’s District V Ethics Committee

Master, William J. Brennan Jr.-Arthur Vanderbilt Inn of Court

Member, BioNJ Legal, Compliance & Regulatory Advisory Committee

Member, Third Circuit Bar Association

Member and speaker, Defense Research Institute 

Member, Association of the Federal Bar of New Jersey

Member, William & Mary School of Law Alumni Ambassador and Reunion Committee 

Member, Saint Joseph’s University Law Alumni Society

Past board member, Morristown American Little League Baseball

Eagle Scout, Boy Scouts of America

Honors

Business Today Top 10 Influential Product Liability Lawyer Defending New Jersey’s Industries, 2023

Chambers USA Nationwide Product Liability and Mass Torts, 2020-23

Chambers USA New Jersey Product Liability and Mass Torts, 2022-23

LMG Life Sciences Leading Life Sciences Lawyer, 2020-22

LMG Life Sciences Life Science Star, 2022-23

The Legal 500, Leading Lawyer in Product Liability; Mass Tort and Class Action-Defense: Pharmaceuticals; and Medical Devices, 2022-23

New Jersey Law Journal Mentor Award, 2021

NJBiz Leaders in Law, 2021

Benchmark Litigation Top Litigator Under 40, 2017; Under 40 Hot List, 2016; Future Star, 2014-22

Law360 Trial Pro, 2016

Legal Intelligencer 40 Under 40, 2014

New Jersey Law Journal New Leaders of the Bar, 2014

EXPERIENCE
Presentations
  • Presenter, “Cybersecurity, Data Privacy, Insurance & Technology Ethics,” Fordham University School of Law, January 2024
  • Faculty, National Trial Advocacy College at the University of Virginia School of Law, January 2024
  • Presenter, "The Attorney Client Privilege for “Predominantly Legal” Communications: Black, White, and Shades of Gray," The Association of the Federal Bar of the District of New Jersey, May 2023
  • Chair, “Current Issues in Pharmaceutical, Medical Device, and Biotech Litigation Conference,” American Bar Association, March 2023
  • Moderator, “In-House Counsel Roundtable,” American Bar Association Section of Litigation, March 2023
  • Presenter, “Foundations and Current Trends in Product Liability and Mass Torts,” February 2023
  • Presenter, “Partnering with Clients, Co-Counsel, and Vendors to Succeed in Cross Border Discovery and Litigation,” January 2023
  • Presenter, “Cybersecurity, Data Privacy, Trade Secrets & Technology Ethics,” Fordham University School of Law, January 2023
  • Faculty, National Trial Advocacy College at the University of Virginia School of Law, January 2023
  • Presenter, “Special Challenges in Managing Large Mass Tort Litigations,” George Washington University Law School, November 2022
  • Faculty, “Bolch Judicial Institute Mass Tort MDL Certificate Program, Duke University School of Law, November 2022
  • Emcee and coordinator, Seventh Annual Lawyers for Tri-County Awards Dinner, September 2022
  • Chair and presenter, “Global Discovery: Managing Proportionality, Privacy, Data Protection, and Other Challenges in Cross-Border Litigation Panel,” International Association of Defense Counsel’s 2022 Annual Meeting, Berlin, Germany, July 2022
  • Presenter, “Navigating Remand Trials” and “Third Circuit Case Law Update,” Trial Attorneys of America Annual Meeting, June 2022 
  • Presenter, “Product Liability in Europe: A Fraying System?” MedTech Forum 2022, Barcelona, Spain, May 2022
  • Presenter, “EU’s Collective Redress Directive – What US and OUS Colleagues May Expect,” Product Liability Advisory Council (PLAC) Spring 2022 Conference, April 2022 
  • Presenter, “Cyber Issues,” New Jersey State Bar Association’s In-House Counsel Special Committee, Webinar, April 25, 2022 
  • Presenter, “Proportionality in Cross-Border Discovery,” The Sedona Conference Working Group 6 (WG6) Annual Meeting 2022: Proportionality in Cross-Border Discovery, February 2022
  • Presenter, “Potential Collective Consumer Lawsuits Coming to the EU: The EU’s Collective Redress Directive,” International Association of Defense Counsel (IADC), December 2021 
  • Presenter, “Latest Developments in Electronic Discovery,” 22nd Annual Pharmaceutical and Medical Device Ethics and Compliance Congress, November 2021 
  • Presenter, “Best Practices for the Recovery and Defense of Attorney Fee Claims in State and Federal Court,” New Jersey State Bar Association, September 2021 
  • Presenter, “Emerging Biopharmaceutical Compliance Roundtable, Risk Assessment and Product Liability Litigation Insights for Companies Introducing a Pharmaceutical Product into the Marketplace,” August 2021 
  • Presenter, “The Appropriate Use of Protective Orders of Confidentiality in Complex Litigation and Mass Torts,” August 2021
  • Presenter, “Deep Dive Into New Framework: Prioritizing Custodians Possessing Relevant Information.” GW Discovery Proportionality Benefit-Burden Model Bench-Bar Conference:, George Washington University School of Law, Webinar, March 2021
  • Moderator, “Inside View: Legal and Ethical Considerations for In-House Counsel,” American Bar Association Section of Litigation’s Current Issues in Pharmaceutical, Medical Device, and Biotech Litigation Virtual Regional CLE Program:, February 2021
  • Presenter, “Proportionality in Cross-border Discovery and Investigations,” The Sedona Conference Working Group 6 on International Electronic Information Management, Discovery and Disclosure Annual Meeting, February 2021
  • Faculty, “Cybersecurity and Ethics,” Fordham University School of Law, February 2021
  • Presenter, “A Roundtable on Corporate Risk Assessment and Strategic Crisis Management” Products Liability Advisory Council (PLAC) Annual Conference, November 2021
  • Presenter, “Counsel’s Role in Business Crises: Anticipate, Avoid and Learn From Catastrophes,” International Association of Defense Counsel webinar, October 2020
  • Presenter, “Immunity in the Age of COVID-19,” Products Liability Advisory Council (PLAC), July 2020
  • Moderator, “A Roundtable on Corporate Risk Assessment and Strategic Crisis Management,” Product Liability Advisory Council (PLAC) spring conference, Scottsdale, Arizona, March 2020 
  • Faculty, “Ethical Issues Associated with Trial Practice,” Fordham University School of Law, January 2020
  • Faculty, National Trial Advocacy College, University of Virginia School of Law
Publications
  • "Keeping The Genie In The Bottle: Global Artificial Intelligence Regulations," Barnes & Thornburg Legal Alert, 2023
  • "EU and Japan Reach Landmark Agreement on Cross-Border Data Flow," Barnes & Thornburg Legal Alert, 2023
  • "New Directive for Product Liability Gains EU Committee Approval," Barnes & Thornburg Legal Alert, 2023
  • "Improving Responses To Crises: Incorporating ESG Considerations Into Effective Crisis Management," Barnes & Thornburg Legal Alert, 2023
  • "European Union Moves Toward AI Regulation," Barnes & Thornburg Legal Alert, 2023
  • "Generative AI is Writing Its Own Editorials," Barnes & Thornburg Legal Alert, 2023
  • "Partnering With In-House Counsel To Preserve Attorney-Client Privilege In Data Breach Probes," New Jersey Law Journal, July 2023
  • "New Consumer Product Safety Regulations In The EU," Barnes & Thornburg Legal Alert, 2023
  • United States Drug & Medical Device Litigation Chapter, International Comparative Legal Guide, (Fourth Edition, 2023)
  • “Remote Data, Accessibility, and Trade Secret Protections,” The Legal Intelligencer, March 2023
  • “Protective Trade Secrets in the Remote Work Environment: Techniques and Solutions,” New Jersey Law Journal, October 2022
  • “Protecting Proprietary Information in the Remote Work Environment: Issues to Consider," New Jersey Law Journal, September 2022
  • “As Bellwether Trials Resume, Mass Tort Lawsuits Soar Due to Litigation Funding,” New Jersey Law Journal, July 2022
  • “Keep out: Enhancing medical device cybersecurity,” NJBIZ, July 2022 
  • “Product Liability Laws and Regulations,”  International Comparative Legal Guide, 2022 
  • “Protecting Trade Secrets in the District of New Jersey,” New Jersey Law Journal, June 2022 
  • “District of Delaware Chief Judge’s New Standing Order Requires Disclosure of Third-Party Litigation Funding,” April 2022
  • “Cybersecurity Safeguard Implemented by Superior Court of New Jersey for OUS Web Traffic,” April 2022
  • “The EU’s Collective Redress Directive — Are Collective Redress Suits Already Happening in Some EU Member States?,” March 2022
  • “Protecting Trade Secrets: A New Jersey Overview,” New Jersey Law Journal, March 2022
  • “Eastern District of Virginia Denies Motion to Certify Class, Sheds Light on Rule 23(b)(3) Predominance and Superiority Requirements for Class Actions,” February 2022
  • Guest, “Defense Counsel Journal Highlights – Lessons from a Year in Crisis: Do’s and Don’ts of Crisis Management,” IADC Speaks podcast, January 2022
  • “Lessons From a Year in Crisis: Do’s and Don’ts of Crisis Management,” IADC Defense Counsel Journal, January 2022 
  • “The EU’s Collective Redress Directive — What Is Included and What Is Excluded as Potential Bases for Collective Redress Lawsuits?,” December 2021
  • “Testimony of Witnesses In-State and Out-of-State: Issues to Consider Under NJ Law,” New Jersey Law Journal, December 2021
  • “FDA Issues Draft Guidance for Sponsors and Other Stakeholders on Using Registries as RWD to Support Regulatory Decision-Making,” December 2021
  • “The Interplay Between the EU’s Collective Redress Directive and GDPR,”  Association for Data and Cyber Governance, November 2021 
  • “Global Pandemic Accelerates Trend Toward Use of Real-World Data Sources,” November 2021
  • “FDA Releases Draft Guidance for Sponsors on How to Comply with Study Data Standards When Submitting RWD-Sourced Study Data,” November 2021
  • “FDA Posts Draft Guidance for Pharma Companies, Sponsors, and Researchers on Using Real-World Data from Health Records in Clinical Studies,” October 2021
  • “From Bredice to the Laboratory or the Boardroom: Careful Consideration for Applying the Self-Critical Analysis Privilege in the Review of Internal Process Improvement,” In-House Defense Quarterly, September 2021 
  • “The EU’s Collective Redress Directive — A Look at What Constitutes a ‘Qualified Entity’,” August 2021
  • “FDA issues final rule clarifying its “intended use” regulations for pharmaceuticals and medical devices,” August 2021
  • “District of New Jersey Clarifies New Local Civil Rule Regarding Third-Party Funding Disclosures,” August 2021
  • “New Jersey Ethics Committee: Beware Marketers that “Lead” to Ethics Violations,” July 2021
  • “The EU’s Collective Redress Directive — A Look at What Constitutes a ‘Trader’,” June 2021
  • “FDA Solicits Feedback to Create Consistent Process for Labeling Devices,” June 2021
  • “District of New Jersey Adopts Local Civil Rule Requiring Disclosure of Third-Party Litigation Funding,” June 2021
  • “The EU’s Collective Redress Directive — The Potential for Collective Consumer Lawsuits: An Introduction,” May 2021
  • “District of New Jersey Proposes New Local Civil Rule Requiring Disclosure of Third-Party Litigation Funding,” April 2021
  • “Product Liability Laws and Regulations,” International Comparative Legal Guides (ICLG), 2021 
  • “NJ Federal Court May Require 3rd-Party Funding Disclosures,” Law360, April 2021
  • “SCOTUS Denies Certiorari in Cases Concerning FCA Liability Requirement, Objective Falsity Circuit Split Remains Intact,” February 2021
  • “Cybersecurity Safeguards Implemented by Federal Judiciary for Filing Highly Sensitive Court Documents,” January 2021
  • “Crisis Management: From Anticipation to Action,” Corporate Counsel Magazine, October 2020 
  • “New Jersey Choice of Law,” New Jersey Mass Torts & Class Action Treatise, December 2020
  • “Role of Science and Expert Evidence,” American Bar Association’s Mass Torts in the United States, December 2020 
  • “How In-House Counsel Can Assess Risks and Red Team Global Organizational Threats,” ACC Docket, December 2020 
  • “FDA Issues Guidance on Conduct of Clinical Trials of Medical Products During COVID 19 Pandemic,” October 2020 
  • “Crisis Management: From Anticipation to Action—Tactics for Multinational Companies Navigating Cross-Border Catastrophes,” Corporate Counsel, September 2020 
  • “A Litigator’s Guide to the 2020 New Jersey Rule Amendments,” September 2020
  • “Crisis Management: From Anticipation to Action—Partnering for Success by Assembling a Top Notch Crisis Management Team,” Corporate Counsel, July 2020 
  • “The Key to a Trade Secret Is Secrecy: Third Circuit Agrees Ownership Is Sufficient but Not Necessary to Maintain a Trade Secret Misappropriation Claim,” June 2020
  • En Banc Third Circuit Sends Online Marketplace Liability Issue to Pennsylvania Supreme Court,” June 2020
  • “Crisis Management: From Anticipation to Action—Red Teaming and Premortems,” June 2020
  • “Rejection of Improper “Attorneys’ Eyes Only” Disclosure Process Relating to Attorney-Client Privilege Challenges,” April 2020
  • “FDA Funding Opportunity Announcement: ‘Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional’,” April 2020
  • “FDA Warns Companies about Processing, Distributing and Marketing Unapproved Stem Cell Products,” January 2020
  • “FDA’s Final Guidance: ‘Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions’,” September 2019
  • “Partnering with Co-Counsel, Clients, and Business Personnel to Succeed in Cross-Border Litigation,” July 2019
  • “Third Circuit Holds Online Retailers May Be Liable for Third-Party Products Under Pennsylvania Product Liability Laws,” July 2019
  • “Partnering with Co-Counsel, Clients, and Business Personnel to Succeed in Cross-Border Litigation,” IADC, July 2019 
  • “Manufacturer Representative Liability and Discovery in Pharmaceutical and Medical Device Mass Tort Actions,” DRI, May 2019. 
  • “FDA’s Final Guidance on “Least Burdensome” Principles for Medical Devices,” May 2019
  • “The FDA’s ‘Medical Product Communications That Are Consistent with the FDA-Required Labeling’ Guidance Document,”DRI, April 2019
  • “Protecting and Preserving Privilege in the Corporate Setting,” DRI’s In-House Defense Quarterly, December 2018 
  • “FDA Warns Against Sales Representative’s ‘False and Misleading’ Oral Statements Regarding Prescription Medicine,” October 2018
  • “50 State Damages Caps/Spoliation/Statutes of Limitation & Repose Guide,” International Association of Defense Counsel, June 2018 
  • “Navigating Proportionality in Discovery,” DRI’s For the Defense, May 2018 
  • “Avoiding the Imposition of a Legal Duty on Detail Representatives,” New Jersey Law Journal, May 2018 
  • “Not Edible, But Still Empty: Manufacturers of Non-Food Products are also Targets for Slack Fill Litigation,” April 2018 IADC Defense Counsel Journal 
  • “Doing Discovery in Japan? Ganbatte! Privacy, Propriety, and Preparation,” Legaltech News, March 2018 
  • “When Would a Reasonable Consumer Be Misled by the Product’s Packaging in Slack-Fill Lawsuits?” American Bar Association, February 2018 
  • “Doing Discovery in Japan? Ganbatte!”  The American Lawyer, February 2018 ‘
  • “Company-Generated Documents and Emails Are Not De Facto Business Records,” The Legal Intelligencer, January 2018
  • “Cost-Shifting and Cost-Sharing Approaches Under the Proportionality Principles,” New Jersey Law Journal, December 2017 
  • “Product Liability Regulation & Legislation: Midyear Report,” Law360, June 2017 
  • “Judicial Notice: An Underappreciated and Misapplied Tool of Efficiency,” International Association of Defense Counsel’s Defense Counsel Journal, Vol. 84, No. 2, April 2017 
  • “New Jersey Choice of Law,” New Jersey Mass Torts & Class Action Treatise (New Jersey State Bar Association/New Jersey Law Journal), 2015 
  • “N.J. Confidential: Preventing Trade Secret Misappropriation Through Injunctive Measures,” New Jersey Law Journal, April 2014 
  • “Final FDA Guidance Clarifies Formatting and Content Requirements of ‘Dear Doctor’ Letters without Requiring Behavior Tracking Evaluations,” February 2014
  • “FTC Expands Patent Transfer Rights Reporting Rules,” December 16, 2013
  • “’Dear Doctor’ Letters: FDA Removes Behavior Tracking Recommendations from Proposed Guidance,” August 2013
  • “The FDA Proposes New Rule on Unique Medical Device Identification and Marking Requirements,” August 1, 2012
INSIGHTS & EVENTS
Trending Connect
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to use cookies.